Within-Subject Comparison of Adipose Tissue Viability Following Liposuction

Inclusion Criteria

• Male or female aged 30 to 65 years, inclusive.
• Planned elective liposuction/body contouring procedure involving two or more anatomical areas (e.g., arms, abdomen, flanks, thighs, and/or back) with sufficient distribution to permit collection of paired adipose tissue samples from contralateral or anatomically matched treatment areas.
• Investigator determines the subject is an appropriate candidate for the planned procedure and study participation.
• Adequate adipose tissue is present to permit collection of required paired fat samples without impacting the planned surgical outcome.
• Able to understand and sign the informed consent form.
• Willing and able to comply with study requirements.
• If applicable, female subjects of childbearing potential must have a negative urine pregnancy test on the day of procedure.

Exclusion Criteria

• Prior liposuction or surgical intervention in the planned treatment areas that, in the opinion of the investigator, may affect adipose tissue characteristics or study assessments.
• Prior treatment of the planned treatment areas with energy-based devices (e.g., ultrasound, radiofrequency, laser) that, in the opinion of the investigator, may affect adipose tissue characteristics or study assessments.
• Significant skin laxity, fibrosis, scarring, or other abnormal tissue characteristics in the planned treatment areas that could impact fat harvest quality or comparability between sites.
• Current smoker or use of nicotine-containing products within 4 weeks prior to the procedure.
• Known metabolic or systemic conditions that may affect adipose tissue biology or wound healing, including but not limited to:

• uncontrolled diabetes mellitus
• significant vascular disease
• connective tissue disorders
• Use of medications known to significantly affect fat metabolism, tissue healing, or inflammatory response, including:

• chronic systemic corticosteroids
• immunosuppressive therapies
• GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) within 4 weeks prior to the procedure
• Active local or systemic infection at the time of the procedure.
• Known coagulopathy or use of anticoagulant therapy that cannot be safely discontinued prior to surgery.
• Pregnant or breastfeeding subjects.
• Body mass index (BMI) outside the range of 20-35 kg/m², inclusive.
• Inadequate adipose tissue volume or distribution to permit paired sample collection from contralateral or anatomically matched areas.
• Participation in another interventional clinical study that, in the opinion of the investigator, could interfere with study endpoints.
• Any condition that, in the opinion of the investigator, would make the subject unsuitable for participation or could confound study results.